Fair Value Measurement - Additional Information. (Detail)					3 Months Ended
Mar. 31, 2013 Milestone Payment Arrangement EUR (€)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab USD ($)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab EUR (€)	Mar. 31, 2013 Novozymes Biopharma Sweden Ab Milestone Payment Arrangement EUR (€)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab Milestone Payment Arrangement USD ($)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab Milestone Payment Arrangement EUR (€)	Mar. 31, 2013 Bio Flash Partners Limited Liability Company Minimum USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business acquisition, contingent Payment	€ 1,000,000	$ 5,200,000	€ 4,000,000	€ 1,000,000	$ 1,300,000	€ 1,000,000
Minimum royalty payment							$ 55,000

Amount of potential cash payments that could result from the contingent consideration arrangement.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Name:	us-gaap_BusinessAcquisitionContingentConsiderationPotentialCashPayment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant